Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05690503 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Glutamatergic Modulation as a Treatment for Depressive Symptoms Among Patients With Post-acute Sequelae of COVID (PASC): A Pilot Trial

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated July 16, 2024 (before its estimated June 30, 2025 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Dec 31, 2023 to Jun 30, 2025
    • Trial status: Recruiting to Active, Not Recruiting
    • Study completion date: Dec 31, 2023 to Dec 31, 2025
    • Site details revised
    v5
  2. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Feb 24, 2023 to Mar 20, 2023
    v4
  3. Study title expanded, about 1 wordv3
  4. Start date: Jan 10, 2023 to Feb 24, 2023v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Post-acute sequelae of SARS-CoV2 (PASC), colloquially known as "long-COVID," is thought to affect between 10-30% of all COVID-19 survivors. Patients with PASC also report worsening behavioral health symptoms over time that include new-onset depression, anxiety, and even suicidal behavior. The purpose of this randomized, double-blind, controlled trial is to test the efficacy of a glutamate modulator among PASC patients suffering from new-onset or worsening of depressive symptoms.
Trial Details
NCT Number NCT05690503
Lead Sponsor New York State Psychiatric Institute
Conditions
(from sponsor)		 Post-acute Sequelae of COVID-19, Depressive Symptoms, Cognitive Dysfunction
Related terms Cognitive Dysfunction, Depression, Post-Acute COVID-19 Syndrome
Enrollment 12 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov